Navigation Links
Pharmasset Receives $10 Million of Working Capital

PRINCETON, N.J., March 28 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) received a second loan of $10 million from Horizon Technology Finance under an existing working capital loan agreement that was entered into during September 2007. Pharmasset received the first loan of $10 million in October 2007 and, at its option, may receive a third loan of $10 million by November 30, 2008, provided certain conditions are satisfied.

"We believe that our existing cash resources, together with a third loan available under our working capital agreement and anticipated payments under our existing HCV collaboration agreement with Roche, will be sufficient to fund our projected cash requirements for the next 18 months," stated Kurt Leutzinger, Pharmasset's Chief Financial Officer. "In light of the recent stock market volatility, this facility has proved to be valuable in providing flexibility regarding the timing of any future equity financings."

For each $10 million loan funded, Pharmasset will pay interest only for the first 15 months followed by 30 equal monthly installments of principal and accrued interest. The interest rate for the initial loan and the second loan will be 12%. In addition, upon entering into the working capital loan agreement, Pharmasset issued to Horizon a seven-year warrant to purchase up to 149,377 shares of common stock at an exercise price of $12.05 per share. The warrant is currently exercisable for up to 66,390 shares associated with the first loan and up to 49,793 shares associated with the second loan. The remaining 33,194 shares will become exercisable upon the funding of the third loan if it occurs.

About Horizon

Founded in 2003, Horizon Technology Finance, LLC is an independent venture debt finance company that offers senior and subordinated working capital to emerging technology companies in the information technology and life sciences industries. Horizon provides a compelling alternative to the restrictive structures offered by banks and corporate finance companies.

The Horizon management team has provided debt financing for more than 750 companies over the last 15 years representing more than $2.0 billion in commitments. Horizon has offices in Farmington, CT and Pleasant Hill, CA. For additional information, please go to

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.


Alan Roemer, Vice President

Investor Relations & Corporate Communications

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that Pharmasset does not receive all or any portion of the funds from the working capital loan agreement with Horizon, the risk that we will default on any of the loans causing all of the loans to be immediately due and payable and allowing Horizon to terminate the loan agreement, the risk that adverse events could cause the cessation of the Phase 3 studies and/or our development of clevudine, the risk that the registration clinical trials of clevudine will not be successful or will not provide meaningful data, the risk that we will fail to release final safety and efficacy data from a Phase 1 combination study of R7128 with Pegasys plus Copegus or that such final data will not corroborate our preliminary results, the risk that the on-going or anticipated clinical trials for any one or more of our product candidates will not be successfully developed or will not provide clinically meaningful data and the risk that any one or more of our product candidates will not be commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset Appoints Herbert J. Conrad as a Director
2. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
3. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
4. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
5. Pharmasset Reports Fiscal Year End 2007 Financial Results
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. Pharmasset to Present at Three Investor Conferences in November 2007
8. Pharmasset Accesses up to $30 Million of Working Capital
9. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
10. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
11. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
Post Your Comments:
(Date:11/30/2015)... Md. , Nov. 30, 2015  Northwest Biotherapeutics ... company developing DCVax® personalized immune therapies for solid tumor ... adding an additional independent director, and the Company welcomes ... of allegations in a recent anonymous internet report on ... both initiatives. Linda Powers stated, "We ...
(Date:11/30/2015)... N.J. and PETACH TIKVAH, Israel ... (NASDAQ: BCLI ), a leading developer of adult ... wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded an ... Office of the Chief Scientist (OCS). This grant, the ... Brainstorm for 2015 activities to approximately $1.8 million (approximately NIS7 ...
(Date:11/27/2015)... 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), ... has closed the sale of its global contrast media ... Euronext) in a transaction valued at approximately $270 million. ... a total of approximately 1,000 employees spread across the ... Louis area. This entire workforce and the ...
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is one ... biomarkers market with pharmaceutical companies and diagnostic ... diagnostic tests. . ... Complete report on global cancer biomarkers market ...
Breaking Biology Technology:
(Date:11/12/2015)... Nov. 11, 2015   Growing need for ... tools has been paving the way for use ... of discrete analytes in clinical, agricultural, environmental, food ... predominantly used in medical applications, however, their adoption ... due to continuous emphasis on improving product quality ...
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
(Date:10/29/2015)... Va. , Oct. 29, 2015 Daon, ... today that it has released a new version of ... customers in North America have ... IdentityX v4.0 also includes a FIDO UAF certified ... are already preparing to activate FIDO features. These customers ...
Breaking Biology News(10 mins):